{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:34:39Z","timestamp":1764174879680,"version":"build-2065373602"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hurvis Family Foundation"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,8,18]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Most adoptive cell therapies (ACTs) suffer from an inability to control the therapeutic cell\u2019s behavior following its transplantation into a patient. Thus, efforts to inhibit, activate, differentiate or terminate an ACT after patient reinfusion can be futile, because the required drug adversely affects other cells in the patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We describe here a two domain fusion receptor composed of a ligand-binding domain linked to a recycling domain that allows constitutive internalization and trafficking of the fusion receptor back to the cell surface. Because the ligand-binding domain is designed to bind a ligand not normally present in humans, any drug conjugated to this ligand will bind and endocytose selectively into the ACT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In two embodiments of our strategy, we fuse the chronically endocytosing domain of human folate receptor alpha to either a murine scFv that binds fluorescein or human FK506 binding protein that binds FK506, thereby creating a fusion receptor composed of largely human components. We then create the ligand-targeted drug by conjugating any desired drug to either fluorescein or FK506, thereby generating a ligand-drug conjugate with ~10<jats:sup>-9<\/jats:sup> M affinity for its fusion receptor. Using these tools, we demonstrate that CAR T cell activities can be sensitively tuned down or turned off in vitro as well as tightly controlled following their reinfusion into tumor-bearing mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We suggest this \u2018chimeric endocytosing receptor\u2019 can be exploited to manipulate not only CAR T cells but other ACTs following their reinfusion into patients. With efforts to develop ACTs to treat diseases including diabetes, heart failure, osteoarthritis, cancer and sickle cell anemia accelerating, we argue an ability to manipulate ACT activities postinfusion will be important.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000756","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T17:05:41Z","timestamp":1604077541000},"page":"e000756","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-137X","authenticated-orcid":false,"given":"Boning","family":"Zhang","sequence":"first","affiliation":[{"name":"Chemistry, Purdue University System, West Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Victor","family":"Napoleon","sequence":"additional","affiliation":[{"name":"Chemistry, Purdue University System, West Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Chemistry, Purdue University System, West Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Luo","sequence":"additional","affiliation":[{"name":"Chemistry, Purdue University System, West Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3056-4571","authenticated-orcid":false,"given":"Madduri","family":"Srinivasarao","sequence":"additional","affiliation":[{"name":"Chemistry, Purdue University System, West Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S","family":"Low","sequence":"additional","affiliation":[{"name":"Chemistry, Purdue University System, West Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"2025100306182325000_8.2.e000756.1","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2001.0504"},{"key":"2025100306182325000_8.2.e000756.2","doi-asserted-by":"publisher","DOI":"10.1038\/73128"},{"key":"2025100306182325000_8.2.e000756.3","doi-asserted-by":"crossref","DOI":"10.1038\/srep19111","article-title":"Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes","volume":"6","author":"Funakoshi","year":"2016","journal-title":"Sci Rep"},{"key":"2025100306182325000_8.2.e000756.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608368"},{"key":"2025100306182325000_8.2.e000756.5","doi-asserted-by":"publisher","DOI":"10.1038\/nri1592"},{"key":"2025100306182325000_8.2.e000756.6","doi-asserted-by":"publisher","DOI":"10.1038\/nm1147"},{"key":"2025100306182325000_8.2.e000756.7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100306182325000_8.2.e000756.8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front Pharmacol"},{"key":"2025100306182325000_8.2.e000756.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564"},{"key":"2025100306182325000_8.2.e000756.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077"},{"key":"2025100306182325000_8.2.e000756.11","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201000222"},{"key":"2025100306182325000_8.2.e000756.12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/mp400659t","article-title":"Effect of receptor occupancy on folate receptor internalization","volume":"11","author":"Bandara","year":"2014","journal-title":"Mol Pharm"},{"key":"2025100306182325000_8.2.e000756.13","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.200800806"},{"key":"2025100306182325000_8.2.e000756.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.08.019"},{"key":"2025100306182325000_8.2.e000756.15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00411"},{"key":"2025100306182325000_8.2.e000756.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01425","article-title":"FKBP Ligands-Where we are and where to go?","volume":"9","author":"Kolos","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025100306182325000_8.2.e000756.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018556"},{"key":"2025100306182325000_8.2.e000756.18","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1016\/S0021-9258(19)81619-8","article-title":"COOH-terminal requirements for the correct processing of a phosphatidylinositol-glycan anchored membrane protein","volume":"263","author":"Berger","year":"1988","journal-title":"J Biol Chem"},{"key":"2025100306182325000_8.2.e000756.19","doi-asserted-by":"publisher","DOI":"10.1021\/ar7000815"},{"key":"2025100306182325000_8.2.e000756.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"2025100306182325000_8.2.e000756.21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-Drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"key":"2025100306182325000_8.2.e000756.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4519"},{"key":"2025100306182325000_8.2.e000756.23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703472"},{"key":"2025100306182325000_8.2.e000756.24","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood.V95.6.2157","article-title":"Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice","volume":"95","author":"Terpstra","year":"2000","journal-title":"Blood"},{"key":"2025100306182325000_8.2.e000756.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09078-0"},{"key":"2025100306182325000_8.2.e000756.26","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.003723"},{"key":"2025100306182325000_8.2.e000756.27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"2025100306182325000_8.2.e000756.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1620498114"},{"key":"2025100306182325000_8.2.e000756.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2314"},{"key":"2025100306182325000_8.2.e000756.30","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-011-0159-1"},{"key":"2025100306182325000_8.2.e000756.31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/sctm.17-0282","article-title":"Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions","volume":"7","author":"Bauer","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"2025100306182325000_8.2.e000756.32","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.181696"},{"key":"2025100306182325000_8.2.e000756.33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"2025100306182325000_8.2.e000756.34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"2025100306182325000_8.2.e000756.35","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ac6138"},{"key":"2025100306182325000_8.2.e000756.36","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1182\/blood.V96.10.3392.h8003392_3392_3398","article-title":"High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors","volume":"96","author":"Salmon","year":"2000","journal-title":"Blood"},{"key":"2025100306182325000_8.2.e000756.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063037","article-title":"Engineering T cell function using chimeric antigen receptors identified using a DNA library approach","volume":"8","author":"Duong","year":"2013","journal-title":"PLoS One"},{"key":"2025100306182325000_8.2.e000756.38","doi-asserted-by":"publisher","DOI":"10.1021\/bc0200430"},{"key":"2025100306182325000_8.2.e000756.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601455103"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:18:36Z","timestamp":1759497516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,30]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jitc-2020-000756"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000756","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}